Xin Yi Wang
Direttore/Membro del Consiglio presso VANFUND URBAN INVESTMENT AND DEVELOPMENT CO., LTD.
Provenienza dei contatti di primo grado di Xin Yi Wang
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Packaged Software | 16 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Xin Yi Wang tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| PENGQI TECHNOLOGY DEVELOPMENT CO., LTD. | Industrial Machinery | Chairman | |
| Southwest University | College/University | Undergraduate Degree | |
Wisefund Investment Holding Group Co., Ltd.
 Wisefund Investment Holding Group Co., Ltd. Real Estate DevelopmentFinance Wisefund Investment Holding Group Co., Ltd. is an investment holding company based in China. The Chinese company has interests in real estate development and mining, among other industries. Bin Hang has been the CEO of the company since 2004. | Real Estate Development | President | |
| TIBET AIM PHARM. INC. | Pharmaceuticals: Other | Director/Board Member | |
Harbin Zhudinggongda New Materials Technology Co., Ltd.
 Harbin Zhudinggongda New Materials Technology Co., Ltd. Other Metals/MineralsNon-Energy Minerals Harbin Zhudinggongda New Materials Technology Co., Ltd. is a company that manufactures non-ferrous metal alloy materials. The company is based in Harbin, China. The Chinese company was founded in 2015. The CEO is Da Wei Xing. | Other Metals/Minerals | Director/Board Member | |
Jilin Wanfang Baiao Biotechnology Co., Ltd.
 Jilin Wanfang Baiao Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Vanfund Urban Investment & Development Co., Ltd., Jilin Wanfang Baiao Biotechnology Co., Ltd. manufactures and sells pharmaceutical products. The company is based in Changchun, China. The Chinese company was founded in 2020. The CEO is Feng Chun Qi. Jilin Wanfang Baiao Biotechnology Co. was acquired by Vanfund Urban Investment & Development Co., Ltd. on January 26, 2022 for $3.29 million. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Cina | 6 |
| Stati Uniti | 2 |
Settori
| Health Technology | 3 |
| Producer Manufacturing | 2 |
| Consumer Services | 2 |
| Finance | 2 |
| Non-Energy Minerals | 2 |
Posizioni
| Director/Board Member | 17 |
| Independent Dir/Board Member | 6 |
| Chairman | 4 |
| Corporate Secretary | 4 |
| Chief Executive Officer | 2 |
Contatti più connessi
| Insiders | |
|---|---|
| Yu Liu | 3 |
| Xing Gang Xiao | 3 |
| Hui Zhang | 2 |
| Zi Bin Guo | 2 |
| Zhi Wang Chen | 2 |
| Han Hui Zhang | 2 |
| Jun Zhang | 1 |
| Na Ni | 1 |
| Chun Jing Wei | 1 |
| Ge Lin Liu | 1 |
| Jian Qing Su | 1 |
| Chao Zhang | 1 |
| Zong Li Zhang | 1 |
| Wei Qiang Song | 1 |
| Li Li Sun | 1 |
- Borsa valori
- Insiders
- Xin Yi Wang
- Connessioni Società
